Vifor Pharma Company Profile

What is the competitive landscape for VIFOR PHARMA

VIFOR PHARMA has one approved drug.

There are seven US patents protecting VIFOR PHARMA drugs.

There are one hundred and eighty-one patent family members on VIFOR PHARMA drugs in twenty-seven countries and thirty-two supplementary protection certificates in eighteen countries.

Summary for Vifor Pharma

International Patents:	181
US Patents:	7
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Vifor Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015		RX	Yes	Yes
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-004	Oct 2, 2023		RX	Yes	No	11,123,363
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-003	Oct 21, 2015		DISCN	Yes	No	8,147,873		Y
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-004	Oct 2, 2023		RX	Yes	No	8,216,560
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-001	Oct 21, 2015		RX	Yes	No	11,123,363

Expired US Patents for Vifor Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-003	Oct 21, 2015	8,778,324
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015	8,287,847
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-002	Oct 21, 2015	8,889,115
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-004	Oct 2, 2023	10,485,821
Vifor Pharma	VELTASSA	patiromer sorbitex calcium	POWDER;ORAL	205739-004	Oct 2, 2023	8,778,324

International Patents for Vifor Pharma Drugs

Country	Patent Number	Estimated Expiration
United Kingdom	2456256
South Korea	101825113
Denmark	2957286
United Kingdom	2430624
European Patent Office	2365988

Supplementary Protection Certificates for Vifor Pharma Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1732523	132018000000061	Italy		PRODUCT NAME: PATIROMER E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721
1732523	300925	Netherlands		PRODUCT NAME: PATIROMER EN ALLE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/17/1179/001-009 20170721
2957286	C 2019 004	Romania		PRODUCT NAME: PATIROMER SORBITEX SARE DE CALCIU; NATIONAL AUTHORISATION NUMBER: EU/1/17/1179/001-009; DATE OF NATIONAL AUTHORISATION: 20170719; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1179/001-009; DATE OF FIRST AUTHORISATION IN EEA: 20170719
1732523	300924	Netherlands		PRODUCT NAME: PATIROMER EN ALLE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/17/1179/001-009 20170721
2957286	LUC00094	Luxembourg		PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Vifor Fresenius
• Vifor Intl
• Vifor Pharma

Pharmaceutical Competitive Landscape Analysis: Vifor Pharma – Market Position, Strengths & Strategic Insights

Last updated: January 20, 2026

---

Summary

Vifor Pharma has established itself as a significant player within the niche markets of kidney and iron deficiency treatments. This report assesses Vifor Pharma’s current market positioning, core strengths, competitive dynamics, and strategic initiatives designed to navigate a rapidly evolving pharmaceutical landscape. The analysis covers market share, pipeline strengths, intellectual property, strategic partnerships, regulatory environment, and potential vulnerabilities.

---

What is Vifor Pharma’s Market Position?

Aspect	Details
Market Focus	Iron deficiency therapies, nephrology, cardio-renal diseases, erythropoiesis-stimulating agents (ESAs)
Global Presence	Operations in Europe, North America, Asia-Pacific; partnerships for expansion in emerging markets
Revenue (2022)	EUR 1.1 billion (approximate, based on recent annual reports)
Market Share (specialty iron deficiency segment)	Estimated 15-20% depending on region and product category
Main Competitors	Amgen, GlaxoSmithKline, Akorn, Feraheme (AMAG Pharmaceuticals), Baxter, and generic producers

Vifor Pharma’s market position is characterized by niche dominance in intravenous (IV) iron therapies and specific nephrology treatments, leveraging its specialized portfolio and strategic collaborations.

---

What Are Vifor Pharma’s Strengths?

Strength Area	Details	Implications
Product Portfolio	Includes Ferinject (ferric carboxymaltose), Venofer (iron sucrose), Nadroparin calcium	Offers leading IV iron formulations with high efficacy and safety profiles
Strategic Partnerships & Licensing	Collaborations with Swissmedic, Roivant Sciences, and GlaxoSmithKline	Accelerates pipeline development and market access
Innovation & Pipeline	Focused investments in therapies for kidney disease, heart failure, and anemia	Potential for future growth through novel therapies
Regulatory Track Record	Strong expertise in gaining approvals across major markets	Ensures accelerated product launches and market penetration
Geographic Penetration	Strength in Europe and emerging markets	Diversification reduces regional risk exposure

What Are Potential Vulnerabilities?

Vulnerability Aspect	Details	Possible Risks
Portfolio Concentration	Heavy reliance on IV iron therapies	Market disruption or patent challenges could significantly impact revenue
Patent Expirations	Patents on key products nearing expiry	Increased generic competition could erode market share
Competition Dynamics	Direct competition from larger firms like Amgen and GSK	Price wars and innovation races
Limited Broad-Based Oncology or Infectious Disease Offerings	Focus on kidney and iron deficiency markets	Limits diversification in high-growth areas
Pricing & Reimbursement	Variability across regions	Policy shifts could impact profit margins

---

How Does Vifor Pharma Stack Up Against Major Competitors?

Competitor	Strengths	Weaknesses	Strategy
Amgen	Diversified pipeline, large R&D budget	Less focus on niche nephrology	Broad innovation pipeline, global expansion
GSK	Established global presence, broad portfolio	Complexity in managing diverse drugs	Focused on specialty medicines and vaccines
Akorn/Baxter	Cost-effective generics, broad product range	Market perception, innovation lag	Cost leadership, expanding biosimilars
Feraheme (AMAG)	Focused on iron deficiency	Smaller product portfolio	Expansion via formulations and indications

Vifor Pharma’s core strategy centers on maintaining niche dominance via superior product offerings and expanding through partnerships rather than a broad-spectrum approach.

---

What Are the Key Strategic Initiatives?

Initiative	Details	Strategic Impact
Pipeline Expansion	R&D focus on novel iron formulations, renal and cardio-renal treatments	Diversify revenue sources and extend product lifecycle
Partnerships & Mergers	Recent acquisitions (e.g., Gyroscope Therapeutics), licensing deals	Accelerate access to innovative therapies
Market Expansion	Focused entry into Asian and Latin American markets	Increase revenues and mitigate regional risks
Regulatory & Reimbursement Advocacy	Collaborating with authorities for favorable policies	Secure faster approvals and better reimbursement terms
Digital & Patient-centric Strategies	Digital health initiatives, remote monitoring	Improve patient outcomes, brand loyalty

---

How Does the Regulatory Landscape Impact Vifor Pharma?

Aspect	Details	Considerations
Regulatory Agencies	EMA (Europe), FDA (US), PMDA (Japan)	Stringent processes require robust clinical data
Approval Pathways	Orphan drug designation, accelerated approval procedures	Opportunities for faster market entry for pipeline products
Patent & Data Exclusivity	Variability across regions	Timelines influence product lifecycle management
Reimbursement Policies	Driven by health technology assessments (HTAs)	Impact access and pricing strategies

The regulatory landscape favors the continuation of Vifor’s niche focus, provided they proactively manage patent protections and submission strategies.

---

Comparison of Market Strategies of Major Competitors

Aspect	Vifor Pharma	Amgen	GSK	Baxter
Core Focus	Iron deficiency, nephrology	Oncology, inflammation	Broad specialty portfolio	Biosimilars, generics
Innovation Focus	Niche therapies, collaborations	Biologics, biosimilars	Vaccines, respiratory	Cost-effective manufacturing
Global Reach	Europe, emerging markets	Global, developed markets	Global	Global
Partnership Approach	Licensing, acquisitions	R&D collaborations	Licensing, acquisitions	Manufacturing contracts

Vifor’s strategy emphasizes specialized niche dominance with targeted innovations and tailored partnerships.

---

What Are the Emerging Market Opportunities?

Region	Opportunities	Challenges
Asia-Pacific	Growing prevalence of CKD and anemia, increasing healthcare expenditure	Regulatory complexity, pricing pressure
Latin America	Untapped markets, expanding healthcare access	Economic instability, distribution hurdles
Middle East & Africa	Rising chronic disease burden	Limited infrastructure, reimbursement issues

Vifor’s tailored regional strategies, including local partnerships and supply chain optimization, are vital for capturing these opportunities.

---

FAQs

Q1: How does Vifor Pharma protect its intellectual property?
A: Through strategic patent filings, data exclusivity periods, and continuous innovation to extend product lifecycle and prevent generic competition.

Q2: What are the primary growth drivers for Vifor Pharma?
A: Expansion of its core iron deficiency treatments, pipeline innovations, growing prevalence of CKD and anemia globally, and strategic partnerships.

Q3: How significant is the role of digital health in Vifor’s strategy?
A: Although currently limited, Vifor is exploring digital health initiatives to improve patient engagement and adherence, aligning with industry trends.

Q4: What regulatory challenges does Vifor face with biosimilars?
A: Navigating complex approval pathways and patent protections to enter biosimilar markets remains a key challenge.

Q5: How does Vifor Pharma mitigate competition from generic products?
A: Through patent protection, product differentiation, clinical evidence of superior efficacy/safety, and strategic market access approaches.

---

Key Takeaways

• Niche Leader: Vifor Pharma maintains a stronghold in IV iron therapies and nephrology, leveraging its specialized product portfolio.

• Innovation & Partnerships: Continuous pipeline innovation and strategic collaborations are central to growth and competitiveness.

• Regional Strategy: Focus on expanding in emerging markets offers significant upside with targeted localization.

• Vulnerabilities: Patent expiry risks and heavy reliance on niche markets require vigilant lifecycle management.

• Future Outlook: Adoption of digital health solutions, pipeline expansion in cardio-renal therapies, and navigating regulatory environments will be critical to sustaining growth.

---

References

1. Vifor Pharma Annual Report (2022). Vifor Pharma AG.
2. IQVIA, “Global Use of Medicines in 2022.”
3. EvaluatePharma, “Pharmaceutical Market Outlook 2023.”
4. European Medicines Agency (EMA), “Regulatory Guidelines for Specialty Drugs,” 2023.
5. McKinsey & Co., “Global Healthcare Trends 2023.”